Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

October’s top stories: Orexigen files authorisation application for Contrave

Orexigen has submitted a marketing authorisation application to the European Medicines Agency for its Contrave drug, while Xencor has dosed the first patient in the Phase IIa, part of its ongoing Phase Ib/IIa clinical trial of XmAb5871 for rheumatoid arthritis, an autoimmune disease. Drugdevelopment-technology.com wraps up the key headlines from October 2013.

Go Top